$22.86−0.62 (−2.64%)
At close: Oct 1, 2026, 4:00 PM ET
GH Research PLC · Overview
Industry: Drugs · see every company filed here →
GH Research PLC scores 57/100. Mixed. Strongest on financial health, quality is the soft spot versus 400 Healthcare peers. Insufficient inputs: Tenet 57 is built from 3 of 4 pillars, from 25% of its inputs. The pillars showing a dash had no data.
Tenet Score · vs sector
n=400Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value41
Quality35
Health97
Growth—
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
Growth omitted — no data yet.
ValueDQualityDHealthA+Growth—MomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
—
no P/E on file
P/B
5.1×
cap ÷ fiscal 2025 book value, Oct 1, 2026 close
P/S
—
no P/S on file
ROE
—
no ROE for this period
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
34.13Tenet-derived How many dollars of assets due within a year the company holds for each dollar of bills due within a year. Computed by Tenet from the filed statements (formula stmt.v1), because the data vendor published no value for this year.
computed by Tenet from the filed statements
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
$1.4B
small cap
Div yield
—
no yield on file
52-wk range
12.04 – 31.44
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
2 / 17
- ✕ Piotroski F-Score
- ✓ Drawdown Context
- ✓ Reversal Evidence
- ~ Not-a-Value-Trap Gate
- ✕ Quality Floor
- ✕ Qualified Dip
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
TBA
next reportBeat/miss history appears here after the first tracked report.Statistics
ROIC−15%
Debt / equity0.00
Technical Analysis
Mixed short-term signalvs 50-day−17.8%
vs 200-day+9.3%
RSI (14)30
News & Insights
Headlines are on the News tab.Dividends
Pays no dividend. Every dollar of profit is reinvested into the business.Ownership
62% institutional
13F flows & insider trades land here.
About GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for th…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold GHRS, and at what weight. Everything else on this page stays open.Create a free account